Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders

Back to results

Primary Purpose

Status

Completed

Phase

Phase 4

Locations

United States

Study Type

Interventional

Intervention

Olanzapine

Clozapine

About this trial

This is an interventional treatment trial for Childhood Schizophrenia focused on measuring Clozapine, Olanzapine, Drug Response, Safety, Childhood Onset Schizophrenia, Schizoaffective Disorder, Multidimensionally Impaired Syndrome, Phenomenology, Biochemical Correlates, Brain Imaging, Schizophrenia, Childhood Schizophrenia, Psychosis

Eligibility Criteria

7 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

INCLUSION CRITERIA: Males and females, age 7 to 18 years Onset of psychotic symptoms before 13th birthday and a DSM-IV diagnosis of either schizophrenia, schizoaffective disorder, MDI syndrome, or psychosis NOS (not otherwise specified). Current significant impairment due to the illness (current psychotic symptoms, decline of functioning academically and socially, significant discomfort due to psychotic symptoms). Failure of two prior trials with antipsychotic medications (either typical or atypical) used at adequate doses (greater than or equal to 100 mg/day in chlorpromazine equivalents) and for adequate duration (at least 4 weeks, unless terminated due to intolerable side effects). Failure is defined as either insufficient response with persistence of symptoms significantly impairing child's functioning, according to child's and parental reports and medical and school records, or intolerable side effects to drugs other than clozapine and olanzapine. Subjects may be included if their previous trial(s) of olanzapine failed to reach the dose of 20. mg/day or a duration of fewer than four weeks. Subjects may be included if their previous trial(s) of clozapine failed to reach the dose of 200. mg/day or a duration of fewer than six weeks. Comorbid psychiatric disorders in the past 12 months are permitted as long as not clinically significant. EXCLUSION CRITERIA: Prepsychotic full-scale IQ less than 70. Unstable major neurological or medical conditions. Current pregnancy or plan to become pregnant during the first three months (the duration of the study) in woman of childbearing age; breast-feeding in woman with infants. DSM-IV substance abuse or dependence in the past 6 months. True non-responders to either olanzapine or clozapine. True non-response is defined as: a) intolerance to either of the medications preventing an adequate trial, or b) only minimal (less than 20%) benefit with the adequate trial of either of the medications. Adequate trial constitutes at least 8 weeks of the medication with the dose of 20 mg on olanzapine or 200 mg of clozapine.

Sites / Locations

National Institutes of Health Clinical Center, 9000 Rockville Pike

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Arm Label

Olanzapine

Clozapine

Arm Description

Outcomes

Primary Outcome Measures

Change in the Scale for the Assessment of Negative Symptoms

Measures change in affective flattening or blunting, alogia, avolition/apathy, anhedonia/asociality, attention; minimum score = 0; maximum score = 125; lower values are considered a better outcome

Change in the Clinical Global Impression Severity of Symptoms Scale

Measures change in the severity of symptoms; Minimum score = 1; maximum score = 7; lower score is considered a better outcome.

Change in the Brief Psychiatric Rating Scale-24

A 24-item scale measuring change in interpersonal behaviors, mood, psychosis, anxiety, speech, sleep, orientation and physical activity. Lowest score = 24; highest score = 168; lower score is considered a better outcome.

Change in the Scale for the Assessment of Positive Symptoms

Measures change in hallucinations, delusions, bizarre behavior, and thought organization. Minimum score = 0; maximum score = 170; lower score is considered a better outcome.

Change in the Bunney-Hamburg Rating Scale for Psychosis

Measures change in psychosis severity; Minimum score = 0; maximum score = 7; lower score is considered a better outcome.

Change in Bunney-Hamburg Rating Scale for Depression

Measures change in severity of depression; Minimum score = 0; maximum score = 7; lower score is considered a better outcome.

Change in Bunney-Hamburg Rating Scale for Mania

Measures change in the severity of mania; Minimum score = 0; maximum score = 7; lower score is considered a better outcome.

Change in the Bunney-Hamburg Rating Scale for Anxiety

Measures change in the severity of anxiety; Minimum score = 0; maximum score = 7; lower score is considered a better outcome.

Secondary Outcome Measures

Full Information

NCT ID

NCT00001656

First Posted

November 3, 1999

Last Updated

March 11, 2011

Sponsor

National Institute of Mental Health (NIMH)

1. Study Identification

Unique Protocol Identification Number

NCT00001656

Brief Title

Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders

Official Title

Childhood Onset Psychotic Disorders: Characterization and Treatment With Atypical Neuroleptics

Study Type

Interventional

2. Study Status

Record Verification Date

March 2011

Overall Recruitment Status

Completed

Study Start Date

June 1997 (undefined)

Primary Completion Date

June 2008 (Actual)

Study Completion Date

June 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor

National Institute of Mental Health (NIMH)

4. Oversight

Data Monitoring Committee

No

5. Study Description

Brief Summary

The purpose of this study is to compare the effectiveness and side effects of the drugs clozapine and olanzapine in children and adolescents with schizophrenia and psychoses. Childhood psychosis is a serious disorder that may have devastating consequences. Effective treatments for the condition are under continual investigation. This study will examine the causes of and offer treatment for childhood psychosis. Participants in this study will undergo psychological tests, blood and urine tests, electroencephalogram (EEG), electrocardiogram (EKG), and magnetic resonance imaging (MRI) scans of the brain for the first 1 to 2 weeks of the study while taking their regular medications. Participants will then be tapered off their medications over 1 to 3 weeks and will continue to stay off medications for an additional 2 days to 3 weeks. During this time, participants will undergo psychiatric, neurological, and cardiac examinations as well as blood tests. After this period without medications, participants will be randomly assigned to receive either clozapine or olanzapine for 8 weeks. An EEG will be performed prior to treatment and after 6 weeks of study medication. Participants who respond well to the study drugs may continue to receive them through their own physician. Participants who do not respond to either clozapine or olanzapine or cannot tolerate their side effects will be treated individually with other drugs until optimum treatment is identified. Regular telephone updates and in person visits to NIH for repeat testing and MRIs will be conducted.

Detailed Description

The purpose of this protocol is to compare efficacy of clozapine and olanzapine in children and adolescents with schizophrenia and psychoses, as well as to learn about side effects of these medication in pediatric population. The underlying hypothesis is that clozapine has superior efficacy over olanzapine. Children and adolescents, ages 7 to 18 years, meeting DSM-IV criteria for schizophrenia, schizoaffective disorder and psychotic disorder not otherwise specified, with onset of psychosis before their 13th birthday, who have not responded to at least two prior trials with typical or a typical neuroleptics, will be eligible to participate in a double-blind, parallel group, trial of olanzapine-clozapine. This study will be done in conjunction with the Screening protocol, which will include characterization by clinical phenomenology, eye tracking, MRI brain imaging, plasma biochemistry, and chromosomal analysis. This study will consist of the following phases 1) Tapering of psychotropic medications (1-4 weeks, depending upon type and dosage). 2) Observation for up to 2 weeks drug free, in order to establish a baseline prior to starting medication trial. 3) An 8 week double-blind trial of either clozapine or olanzapine. Efficacy and tolerability of clozapine and olanzapine will be compared using specified criteria. 4) If desired improvement not achieved or trial is interrupted, an 8 week open trial of the second medication and 5) Discharge following medication optimization for up to 4 weeks, or as clinically appropriate. This protocol also includes a follow-up every 2 to 3 years for a period of 10 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Childhood Schizophrenia, Psychotic Disorder, Schizophrenia

Keywords

Clozapine, Olanzapine, Drug Response, Safety, Childhood Onset Schizophrenia, Schizoaffective Disorder, Multidimensionally Impaired Syndrome, Phenomenology, Biochemical Correlates, Brain Imaging, Schizophrenia, Childhood Schizophrenia, Psychosis

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 4

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigator

Allocation

Randomized

Enrollment

25 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Olanzapine

Arm Type

Active Comparator

Arm Title

Clozapine

Arm Type

Active Comparator

Intervention Type

Drug

Intervention Name(s)

Olanzapine

Other Intervention Name(s)

"Zyprexa"

Intervention Description

tablet; 5-20mg/day; 8 weeks

Intervention Type

Drug

Intervention Name(s)

Clozapine

Other Intervention Name(s)

"Clozaril"

Intervention Description

tablet; 12.5-900mg/day; 8 weeks

Primary Outcome Measure Information:

Title

Change in the Scale for the Assessment of Negative Symptoms

Description

Measures change in affective flattening or blunting, alogia, avolition/apathy, anhedonia/asociality, attention; minimum score = 0; maximum score = 125; lower values are considered a better outcome

Time Frame